Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.

Abstract

Vaccines are available against human papillomavirus (HPV), the causal agent of cervical and other cancers. Efficacy data from the HPV-16/18 AS04-adjuvanted vaccine clinical trial program were reviewed. Six randomized, controlled phase II/III trials evaluating cervical endpoints enrolled women from diverse populations and geographical locations. The program analyzed extensively the cohorts most relevant from a public health perspective: the total vaccinated cohort (TVC), approximating a general population including those with existing or previous HPV infection, and TVC-naïve, approximating a population of young women before sexual debut. Results show that the vaccine reduces HPV-16/18 infection and associated cervical endpoints in women regardless of age, location, or sexual experience. It provides cross-protection against some non-vaccine oncogenic HPV types and types causing genital warts, and may be effective against vulvar, oral, and anal HPV infection. Early epidemiology data following its introduction suggest a decline in the prevalence of vaccine and some non-vaccine HPV types.

• Authors: S Rachel Skinner, Dan Apter, Newton De Carvalho, Diane M Harper, Ryo Konno, Jorma Paavonen, Barbara Romanowski, Cecilia Roteli-Martins, Nansa Burlet, Attila Mihalyi, Frank Struyf
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 15 Issue 3 Pg. 367-87 ( 2016) ISSN: 1744-8395 [Electronic] England
• PMID: 26902666 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• ASO4 mixture
• Adjuvants, Immunologic
• Lipid A
• Papillomavirus Vaccines
• Aluminum Hydroxide

Topics

• Adjuvants, Immunologic (administration & dosage)
• Aluminum Hydroxide (administration & dosage)
• Anus Neoplasms (epidemiology, prevention & control)
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Condylomata Acuminata (epidemiology, prevention & control)
• Female
• Human papillomavirus 16 (immunology)
• Human papillomavirus 18 (immunology)
• Humans
• Lipid A (administration & dosage, analogs & derivatives)
• Mouth Neoplasms (epidemiology, prevention & control)
• Papillomavirus Infections (complications, epidemiology, prevention & control)
• Papillomavirus Vaccines (administration & dosage, immunology)
• Randomized Controlled Trials as Topic
• Uterine Cervical Neoplasms (prevention & control)